Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 156
Filter
Add more filters

Publication year range
1.
Am J Respir Crit Care Med ; 209(1): 91-100, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37734031

ABSTRACT

Rationale: Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Prior studies implicated proxy-defined donor smoking as a risk factor for PGD and mortality. Objectives: We aimed to more accurately assess the impact of donor smoke exposure on PGD and mortality using quantitative smoke exposure biomarkers. Methods: We performed a multicenter prospective cohort study of lung transplant recipients enrolled in the Lung Transplant Outcomes Group cohort between 2012 and 2018. PGD was defined as grade 3 at 48 or 72 hours after lung reperfusion. Donor smoking was defined using accepted thresholds of urinary biomarkers of nicotine exposure (cotinine) and tobacco-specific nitrosamine (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol [NNAL]) in addition to clinical history. The donor smoking-PGD association was assessed using logistic regression, and survival analysis was performed using inverse probability of exposure weighting according to smoking category. Measurements and Main Results: Active donor smoking prevalence varied by definition, with 34-43% based on urinary cotinine, 28% by urinary NNAL, and 37% by clinical documentation. The standardized risk of PGD associated with active donor smoking was higher across all definitions, with an absolute risk increase of 11.5% (95% confidence interval [CI], 3.8% to 19.2%) by urinary cotinine, 5.7% (95% CI, -3.4% to 14.9%) by urinary NNAL, and 6.5% (95% CI, -2.8% to 15.8%) defined clinically. Donor smoking was not associated with differential post-lung transplant survival using any definition. Conclusions: Donor smoking associates with a modest increase in PGD risk but not with increased recipient mortality. Use of lungs from smokers is likely safe and may increase lung donor availability. Clinical trial registered with www.clinicaltrials.gov (NCT00552357).


Subject(s)
Lung Transplantation , Primary Graft Dysfunction , Smoking , Tissue Donors , Humans , Biomarkers , Cotinine , Lung Transplantation/adverse effects , Primary Graft Dysfunction/epidemiology , Prospective Studies , Smoking/adverse effects
2.
Am J Transplant ; 24(5): 839-849, 2024 May.
Article in English | MEDLINE | ID: mdl-38266712

ABSTRACT

Lung transplantation lags behind other solid organ transplants in donor lung utilization due, in part, to uncertainty regarding donor quality. We sought to develop an easy-to-use donor risk metric that, unlike existing metrics, accounts for a rich set of donor factors. Our study population consisted of n = 26 549 adult lung transplant recipients abstracted from the United Network for Organ Sharing Standard Transplant Analysis and Research file. We used Cox regression to model graft failure (GF; earliest of death or retransplant) risk based on donor and transplant factors, adjusting for recipient factors. We then derived and validated a Lung Donor Risk Index (LDRI) and developed a pertinent online application (https://shiny.pmacs.upenn.edu/LDRI_Calculator/). We found 12 donor/transplant factors that were independently predictive of GF: age, race, insulin-dependent diabetes, the difference between donor and recipient height, smoking, cocaine use, cytomegalovirus seropositivity, creatinine, human leukocyte antigen (HLA) mismatch, ischemia time, and donation after circulatory death. Validation showed the LDRI to have GF risk discrimination that was reasonable (C = 0.61) and higher than any of its predecessors. The LDRI is intended for use by transplant centers, organ procurement organizations, and regulatory agencies and to benefit patients in decision-making. Unlike its predecessors, the proposed LDRI could gain wide acceptance because of its granularity and similarity to the Kidney Donor Risk Index.


Subject(s)
Graft Rejection , Graft Survival , Lung Transplantation , Tissue Donors , Tissue and Organ Procurement , Humans , Lung Transplantation/adverse effects , Female , Male , Tissue Donors/supply & distribution , Middle Aged , Risk Factors , Adult , Graft Rejection/etiology , Follow-Up Studies , Prognosis , Risk Assessment
3.
Clin Infect Dis ; 72(11): e887-e889, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33053155

ABSTRACT

For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.


Subject(s)
COVID-19 , Humans , Proportional Hazards Models , SARS-CoV-2 , Survival Analysis , Treatment Outcome
4.
JAMA ; 326(11): 1045-1056, 2021 09 21.
Article in English | MEDLINE | ID: mdl-34546296

ABSTRACT

Importance: Mediation analyses of randomized trials and observational studies can generate evidence about the mechanisms by which interventions and exposures may influence health outcomes. Publications of mediation analyses are increasing, but the quality of their reporting is suboptimal. Objective: To develop international, consensus-based guidance for the reporting of mediation analyses of randomized trials and observational studies (A Guideline for Reporting Mediation Analyses; AGReMA). Design, Setting, and Participants: The AGReMA statement was developed using the Enhancing Quality and Transparency of Health Research (EQUATOR) methodological framework for developing reporting guidelines. The guideline development process included (1) an overview of systematic reviews to assess the need for a reporting guideline; (2) review of systematic reviews of relevant evidence on reporting mediation analyses; (3) conducting a Delphi survey with panel members that included methodologists, statisticians, clinical trialists, epidemiologists, psychologists, applied clinical researchers, clinicians, implementation scientists, evidence synthesis experts, representatives from the EQUATOR Network, and journal editors (n = 19; June-November 2019); (4) having a consensus meeting (n = 15; April 28-29, 2020); and (5) conducting a 4-week external review and pilot test that included methodologists and potential users of AGReMA (n = 21; November 2020). Results: A previously reported overview of 54 systematic reviews of mediation studies demonstrated the need for a reporting guideline. Thirty-three potential reporting items were identified from 3 systematic reviews of mediation studies. Over 3 rounds, the Delphi panelists ranked the importance of these items, provided 60 qualitative comments for item refinement and prioritization, and suggested new items for consideration. All items were reviewed during a 2-day consensus meeting and participants agreed on a 25-item AGReMA statement for studies in which mediation analyses are the primary focus and a 9-item short-form AGReMA statement for studies in which mediation analyses are a secondary focus. These checklists were externally reviewed and pilot tested by 21 expert methodologists and potential users, which led to minor adjustments and consolidation of the checklists. Conclusions and Relevance: The AGReMA statement provides recommendations for reporting primary and secondary mediation analyses of randomized trials and observational studies. Improved reporting of studies that use mediation analyses could facilitate peer review and help produce publications that are complete, accurate, transparent, and reproducible.


Subject(s)
Guidelines as Topic , Mediation Analysis , Observational Studies as Topic , Randomized Controlled Trials as Topic , Checklist , Delphi Technique , Humans , Peer Review , Systematic Reviews as Topic
5.
J Allergy Clin Immunol ; 144(3): 846-853.e11, 2019 09.
Article in English | MEDLINE | ID: mdl-31181221

ABSTRACT

BACKGROUND: Asthma disproportionately affects low-income and minority adults. In an era of electronic records and Internet-based digital devices, it is unknown whether portals for patient-provider communication can improve asthma outcomes. OBJECTIVE: We sought to estimate the effect on asthma outcomes of an intervention using home visits (HVs) by community health workers (CHWs) plus training in patient portals compared with usual care and portal training only. METHODS: Three hundred one predominantly African American and Hispanic/Latino adults with uncontrolled asthma were recruited from primary care and asthma specialty practices serving low-income urban neighborhoods, directed to Internet access, and given portal training. Half were randomized to HVs over 6 months by CHWs to facilitate competency in portal use and promote care coordination. RESULTS: One hundred seventy (56%) patients used the portal independently. Rates of portal activity did not differ between randomized groups. Asthma control and asthma-related quality of life improved in both groups over 1 year. Differences in improvements over time were greater for the HV group for all outcomes but reached conventional levels of statistical significance only for the yearly hospitalization rate (-0.53; 95% CI, -1.08 to -0.024). Poor neighborhoods and living conditions plus limited Internet access were barriers for patients to complete the protocol and for CHWs to make HVs. CONCLUSION: For low-income adults with uncontrolled asthma, portal access and CHWs produced small incremental benefits. HVs with emphasis on self-management education might be necessary to facilitate patient-clinician communication and to improve asthma outcomes.


Subject(s)
Asthma/therapy , House Calls , Patient Portals , Adolescent , Adult , Aged , Aged, 80 and over , Community Health Workers , Female , Health Education , Humans , Male , Middle Aged , Poverty , Quality of Life , Young Adult
6.
Clin Infect Dis ; 69(8): 1360-1367, 2019 09 27.
Article in English | MEDLINE | ID: mdl-30596901

ABSTRACT

BACKGROUND: Sepsis is a leading cause of neonatal mortality in low-resource settings. As facility-based births become more common, the proportion of neonatal deaths due to hospital-onset sepsis has increased. METHODS: We conducted a prospective cohort study in a neonatal intensive care unit in Zambia where we implemented a multifaceted infection prevention and control (IPC) bundle consisting of IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing of babies ≥1.5 kg with 2% chlorhexidine gluconate. Hospital-associated sepsis, bloodstream infection (BSI), and mortality (>3 days after admission) outcome data were collected for 6 months prior to and 11 months after bundle implementation. RESULTS: Most enrolled neonates had a birth weight ≥1.5 kg (2131/2669 [79.8%]). Hospital-associated mortality was lower during the intervention than baseline period (18.0% vs 23.6%, respectively). Total mortality was lower in the intervention than prior periods. Half of enrolled neonates (50.4%) had suspected sepsis; 40.8% of cultures were positive. Most positive blood cultures yielded a pathogen (409/549 [74.5%]), predominantly Klebsiella pneumoniae (289/409 [70.1%]). The monthly rate and incidence density rate of suspected sepsis were lower in the intervention period for all birth weight categories, except babies weighing <1.0 kg. The rate of BSI with pathogen was also lower in the intervention than baseline period. CONCLUSIONS: A simple IPC bundle can reduce sepsis and death in neonates hospitalized in high-risk, low-resource settings. Further research is needed to validate these findings in similar settings and to identify optimal implementation strategies for improvement and sustainability. CLINICAL TRIALS REGISTRATION: NCT02386592.


Subject(s)
Anti-Infective Agents, Local/administration & dosage , Bacteremia/prevention & control , Chlorhexidine/analogs & derivatives , Infection Control , Sepsis/prevention & control , Bacteremia/epidemiology , Bacteremia/microbiology , Birth Weight , Chlorhexidine/administration & dosage , Cohort Studies , Hospital Mortality , Hospitals , Humans , Infant , Infant Mortality , Infant, Newborn , Infection Control/methods , Intensive Care Units, Neonatal , Perinatal Death/prevention & control , Prospective Studies , Sepsis/epidemiology , Sepsis/microbiology , Sepsis/mortality , Zambia/epidemiology
8.
J Asthma ; 54(10): 1051-1058, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28332939

ABSTRACT

OBJECTIVE: To examine the effect of ambulatory health care processes on asthma hospitalizations. METHODS: A retrospective cohort study using electronic health records was completed. Patients aged 2-18 years receiving health care from 1 of 5 urban practices between Jan 1, 2004 and Dec 31, 2008 with asthma documented on their problem list were included. Independent variables were modifiable health care processes in the primary care setting: (1) use of asthma controller medications; (2) regular assessment of asthma symptoms; (3) use of spirometry; (4) provision of individualized asthma care plans; (5) timely influenza vaccination; (6) access to primary healthcare; and (7) use of pay for performance physician incentives. Occurrence of one or more asthma hospitalizations was the primary outcome of interest. We used a log linear model (Poisson regression) to model the association between the factors of interest and number of asthma hospitalizations. RESULTS: 5,712 children with asthma were available for analysis. 96% of the children were African American. The overall hospitalization rate was 64 per 1,000 children per year. None of the commonly used asthma-specific indicators of high quality care were associated with fewer asthma hospitalizations. Children with documented asthma who experienced a lack of primary health care (no more than one outpatient visit at their primary care location in the 2 years preceding hospitalization) were at higher risk of hospitalization compared to those children with a greater number of visits (incidence rate ratio 1.39; 95% CI 1.09-1.78). CONCLUSIONS: In children with asthma, more frequent primary care visits are associated with reduced asthma hospitalizations.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/epidemiology , Hospitalization/statistics & numerical data , Primary Health Care/statistics & numerical data , Quality of Health Care/statistics & numerical data , Adolescent , Black or African American/statistics & numerical data , Age Distribution , Anti-Asthmatic Agents/administration & dosage , Asthma/ethnology , Asthma/therapy , Body Mass Index , Child , Child, Preschool , Continuity of Patient Care/statistics & numerical data , Electronic Health Records , Female , Health Services Accessibility/statistics & numerical data , Humans , Influenza Vaccines/administration & dosage , Male , Minority Groups/statistics & numerical data , Patient Care Planning/statistics & numerical data , Reimbursement, Incentive/statistics & numerical data , Retrospective Studies , Severity of Illness Index , Sex Distribution , Spirometry , Urban Population/statistics & numerical data
9.
J Allergy Clin Immunol ; 138(6): 1526-1530, 2016 12.
Article in English | MEDLINE | ID: mdl-27777181

ABSTRACT

Research on asthma frequently recruits patients from clinics because the ready pool of patients leads to easy access to patients in office waiting areas, emergency departments, or hospital wards. Patients with other chronic conditions, and with mobility problems, face exposures at home that are not easily identified at the clinic. In this article, we describe the perspective of the community health workers and the challenges they encountered when making home visits while implementing a research intervention in a cohort of low-income, minority patients. From their observations, poor housing, often the result of poverty and lack of social resources, is the real elephant in the chronic asthma room. To achieve a goal of reduced asthma morbidity and mortality will require a first-hand understanding of the real-world social and economic barriers to optimal asthma management and the solutions to those barriers.


Subject(s)
Asthma/epidemiology , Community Health Workers , House Calls , Adult , Community Networks , Healthcare Disparities , Humans , Patient Outcome Assessment , Poverty , United States
10.
JAMA ; 318(23): 2325-2336, 2017 12 19.
Article in English | MEDLINE | ID: mdl-29260224

ABSTRACT

Importance: Acute respiratory tract infections account for the majority of antibiotic exposure in children, and broad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing. It is not clear whether broad-spectrum treatment is associated with improved outcomes compared with narrow-spectrum treatment. Objective: To compare the effectiveness of broad-spectrum and narrow-spectrum antibiotic treatment for acute respiratory tract infections in children. Design, Setting, and Participants: A retrospective cohort study assessing clinical outcomes and a prospective cohort study assessing patient-centered outcomes of children between the ages of 6 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antibiotic between January 2015 and April 2016 in a network of 31 pediatric primary care practices in Pennsylvania and New Jersey. Stratified and propensity score-matched analyses to account for confounding by clinician and by patient-level characteristics, respectively, were implemented for both cohorts. Exposures: Broad-spectrum antibiotics vs narrow-spectrum antibiotics. Main Outcomes and Measures: In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis. In the prospective cohort, the primary outcomes were quality of life, other patient-centered outcomes, and patient-reported adverse events. Results: Of 30 159 children in the retrospective cohort (19 179 with acute otitis media; 6746, group A streptococcal pharyngitis; and 4234, acute sinusitis), 4307 (14%) were prescribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides. Broad-spectrum treatment was not associated with a lower rate of treatment failure (3.4% for broad-spectrum antibiotics vs 3.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 0.3% [95% CI, -0.4% to 0.9%]). Of 2472 children enrolled in the prospective cohort (1100 with acute otitis media; 705, group A streptococcal pharyngitis; and 667, acute sinusitis), 868 (35%) were prescribed broad-spectrum antibiotics. Broad-spectrum antibiotics were associated with a slightly worse child quality of life (score of 90.2 for broad-spectrum antibiotics vs 91.5 for narrow-spectrum antibiotics; score difference for full matched analysis, -1.4% [95% CI, -2.4% to -0.4%]) but not with other patient-centered outcomes. Broad-spectrum treatment was associated with a higher risk of adverse events documented by the clinician (3.7% for broad-spectrum antibiotics vs 2.7% for narrow-spectrum antibiotics; risk difference for full matched analysis, 1.1% [95% CI, 0.4% to 1.8%]) and reported by the patient (35.6% for broad-spectrum antibiotics vs 25.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 12.2% [95% CI, 7.3% to 17.2%]). Conclusions and Relevance: Among children with acute respiratory tract infections, broad-spectrum antibiotics were not associated with better clinical or patient-centered outcomes compared with narrow-spectrum antibiotics, and were associated with higher rates of adverse events. These data support the use of narrow-spectrum antibiotics for most children with acute respiratory tract infections.


Subject(s)
Anti-Bacterial Agents/adverse effects , Otitis Media/drug therapy , Quality of Life , Respiratory Tract Infections/drug therapy , Acute Disease , Amoxicillin-Potassium Clavulanate Combination/adverse effects , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cephalosporins/adverse effects , Cephalosporins/therapeutic use , Child , Child, Preschool , Female , Humans , Macrolides/adverse effects , Macrolides/therapeutic use , Male , Pharyngitis/drug therapy , Primary Health Care , Retrospective Studies , Sinusitis/drug therapy , Streptococcal Infections/drug therapy , Streptococcus pyogenes , Treatment Failure
11.
Telemed J E Health ; 23(2): 130-136, 2017 02.
Article in English | MEDLINE | ID: mdl-27328326

ABSTRACT

BACKGROUND: Video-capable mobile phones are widely available, but few studies have evaluated their use in telephone triage for pediatric patients. We assessed the feasibility, acceptability, and utility of videos sent via mobile phones to enhance pediatric telephone triage for an underserved population with asthma. MATERIALS AND METHODS: We recruited children who presented to an urban pediatric emergency department with an asthma exacerbation along with their parent/guardian. Parents and the research team each obtained a video of the child's respiratory exam, and the research team conducted a concurrent in-person rating of respiratory status. We measured the acceptability of families sending videos as part of telephone triage (survey) and the feasibility of this approach (rates of successful video transmission by parents to the research team). To estimate the utility of the video in appropriately triaging children, four clinicians reviewed each video and rated whether they found the video reassuring, neutral, or raising concerns. RESULTS: Among 60 families (78% Medicaid, 85% Black), 80% of parents reported that sending a video would be helpful and 68% reported that a nurse's review of a video would increase their trust in the triage assessment. Most families (75%) successfully transmitted a video to the research team. All clinician raters found the video reassuring regarding the severity of the child's asthma exacerbation for 68% of children. CONCLUSIONS: Obtaining mobile phone videos for telephone triage is acceptable to families, feasible, and may help improve the quality of telephone triage in an urban, minority population.


Subject(s)
Asthma/physiopathology , Cell Phone , Remote Consultation/methods , Triage/methods , Videotape Recording , Vulnerable Populations , Child , Child, Preschool , Emergency Service, Hospital/organization & administration , Female , Humans , Male , Socioeconomic Factors , Trust , Urban Health Services/organization & administration
12.
Ann Intern Med ; 172(1): 63-64, 2020 01 07.
Article in English | MEDLINE | ID: mdl-31711098

Subject(s)
Precision Medicine
14.
JAMA ; 315(12): 1258-65, 2016.
Article in English | MEDLINE | ID: mdl-27002447

ABSTRACT

IMPORTANCE: Early-life antibiotic exposure has been associated with increased adiposity in animal models, mediated through the gut microbiome. Infant antibiotic exposure is common and often inappropriate. Studies of the association between infant antibiotics and childhood weight gain have reported inconsistent results. OBJECTIVE: To assess the association between early-life antibiotic exposure and childhood weight gain. DESIGN AND SETTING: Retrospective, longitudinal study of singleton births and matched longitudinal study of twin pairs conducted in a network of 30 pediatric primary care practices serving more than 200,000 children of diverse racial and socioeconomic backgrounds across Pennsylvania, New Jersey, and Delaware. PARTICIPANTS: Children born between November 1, 2001, and December 31, 2011, at 35 weeks' gestational age or older, with birth weight of 2000 g or more and in the fifth percentile or higher for gestational age, and who had a preventive health visit within 14 days of life and at least 2 additional visits in the first year of life. Children with complex chronic conditions and those who received long-term antibiotics or multiple systemic corticosteroid prescriptions were excluded. We included 38,522 singleton children and 92 twins (46 matched pairs) discordant in antibiotic exposure. Final date of follow-up was December 31, 2012. EXPOSURE: Systemic antibiotic use in the first 6 months of life. MAIN OUTCOMES AND MEASURES: Weight, measured at preventive health visits from age 6 months through 7 years. RESULTS: Of 38,522 singleton children (50% female; mean birth weight, 3.4 kg), 5287 (14%) were exposed to antibiotics during the first 6 months of life (at a mean age of 4.3 months). Antibiotic exposure was not significantly associated with rate of weight change (0.7%; 95% CI, -0.1% to 1.5%; P = .07, equivalent to approximately 0.05 kg; 95% CI, -0.004 to 0.11 kg of added weight gain between age 2 years and 5 years). Among 92 twins (38% female; mean birth weight, 2.8 kg), the 46 twins who were exposed to antibiotics during the first 6 months of life received them at a mean age of 4.5 months. Antibiotic exposure was not significantly associated with a weight difference (-0.09 kg; 95% CI, -0.26 to 0.08 kg; P = .30). CONCLUSIONS AND RELEVANCE: Exposure to antibiotics within the first 6 months of life compared with no exposure was not associated with a statistically significant difference in weight gain through age 7 years. There are many reasons to limit antibiotic exposure in young, healthy children, but weight gain is likely not one of them.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Weight Gain/drug effects , Age Factors , Birth Weight , Child , Child, Preschool , Delaware , Female , Gestational Age , Growth/physiology , Humans , Infant , Infant, Newborn , Longitudinal Studies , Male , Matched-Pair Analysis , New Jersey , Pennsylvania , Primary Prevention , Retrospective Studies , Twins, Dizygotic/statistics & numerical data
15.
Am J Epidemiol ; 181(12): 989-95, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-25995287

ABSTRACT

Randomized controlled trials are the "gold standard" for estimating the causal effects of treatments. However, it is often not feasible to conduct such a trial because of ethical concerns or budgetary constraints. We expand upon an approach to the analysis of observational data sets that mimics a sequence of randomized studies by implementing propensity score models within each trial to achieve covariate balance, using weighting and matching. The methods are illustrated using data from a safety study of the relationship between second-generation antipsychotics and type 2 diabetes (outcome) in Medicaid-insured children aged 10-18 years across the United States from 2003 to 2007. Challenges in this data set include a rare outcome, a rare exposure, substantial and important differences between exposure groups, and a very large sample size.


Subject(s)
Data Interpretation, Statistical , Epidemiologic Research Design , Observational Studies as Topic , Propensity Score , Adolescent , Antipsychotic Agents/adverse effects , Causality , Child , Confounding Factors, Epidemiologic , Diabetes Mellitus, Type 2/chemically induced , Female , Humans , Intention to Treat Analysis , Longitudinal Studies , Male , Matched-Pair Analysis , Models, Statistical , Randomized Controlled Trials as Topic
16.
Ann Intern Med ; 160(6): 369-79, 2014 Mar 18.
Article in English | MEDLINE | ID: mdl-24723077

ABSTRACT

BACKGROUND: The incidence and determinants of hepatic decompensation have been incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone. OBJECTIVE: To compare the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART. DESIGN: Retrospective cohort study. SETTING: Veterans Health Administration. PATIENTS: 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment-naive. MEASUREMENTS: Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. RESULTS: The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P < 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients. LIMITATION: Observational study of predominantly male patients. CONCLUSION: Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race. PRIMARY FUNDING SOURCE: National Institutes of Health.


Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/complications , HIV Infections/drug therapy , Hepatitis C, Chronic/complications , Adult , Ascites/epidemiology , Bacterial Infections/epidemiology , Carcinoma, Hepatocellular/epidemiology , Coinfection , Esophageal and Gastric Varices/epidemiology , Female , Gastrointestinal Hemorrhage/epidemiology , HIV/genetics , HIV Infections/virology , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/epidemiology , Humans , Incidence , Liver Neoplasms/epidemiology , Male , Medication Adherence , Middle Aged , Peritonitis/epidemiology , RNA, Viral/blood , Retrospective Studies , Treatment Outcome , Viral Load
17.
Clin Infect Dis ; 58(1): 74-7, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24114736

ABSTRACT

Rates of invasive candidiasis (IC) in children between 2003 and 2011 were evaluated in a retrospective cross-sectional analysis. The rate of IC decreased 72% (P < .001) overall and 91% in neonates (P < .001). Improving infection control efforts is thought to be a contributing factor for this decrease.


Subject(s)
Candidiasis, Invasive/epidemiology , Hospitals, Pediatric , Adolescent , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Infant , Infant, Newborn , Infection Control/methods , Male , Retrospective Studies , United States/epidemiology
18.
Clin Infect Dis ; 58(6): 834-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24399088

ABSTRACT

We examined the impact of the Pediatric Infectious Diseases Society/Infectious Diseases Society of America guidelines that recommend ampicillin or amoxicillin for children hospitalized with community-acquired pneumonia. Prescribing of ampicillin/amoxicillin increased following guideline publication, but remains low. Cephalosporin and macrolide prescribing decreased but remains common. Further studies exploring outcomes of and reasons for compliance with guidelines are warranted.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Community-Acquired Infections/drug therapy , Community-Acquired Infections/epidemiology , Hospitalization/statistics & numerical data , Pneumonia/drug therapy , Pneumonia/epidemiology , Adolescent , Amoxicillin/administration & dosage , Ampicillin/administration & dosage , Child , Child, Preschool , Guideline Adherence , Humans , Infant , Longitudinal Studies , Pediatrics , Practice Guidelines as Topic , Societies, Medical , United States/epidemiology
19.
J Hepatol ; 61(2): 210-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24713185

ABSTRACT

BACKGROUND & AIMS: Chronic hepatitis B (CHB) infection is associated with reduced bone mineral density, but its association with fractures is unknown. Our objectives were to determine whether untreated or treated CHB-infected persons are at increased risk for hip fracture compared to uninfected persons. METHODS: We conducted a cohort study among 18,796 untreated CHB-infected, 7777 treated CHB-infected, and 979,751 randomly sampled uninfected persons within the U.S. Medicaid populations of California, Florida, New York, Ohio, and Pennsylvania (1999-2007). CHB infection was defined by two CHB diagnoses recorded >6 months apart and was classified as treated if a diagnosis was recorded and antiviral therapy was dispensed. After propensity score matching of CHB-infected and uninfected persons, Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of incident hip fracture in: (1) untreated CHB-infected vs. uninfected, and (2) treated CHB-infected vs. uninfected patients. RESULTS: Untreated CHB-infected patients of black race had a higher rate of hip fracture than uninfected black persons (HR, 2.55 [95% CI, 1.42-4.58]). Compared to uninfected persons, relative hazards of hip fracture were increased for untreated white (HR, 1.26 [95% CI, 0.98-1.62]) and Hispanic (HR, 1.36 [95% CI, 0.77-2.40]) CHB-infected patients, and treated black (HR, 3.09 [95% CI, 0.59-16.22]) and white (HR, 1.90 [95% CI, 0.81-4.47]) CHB-infected patients, but these associations were not statistically significant. CONCLUSIONS: Among U.S. Medicaid enrollees, untreated CHB-infected patients of black race had a higher risk of hip fracture than uninfected black persons.


Subject(s)
Hepatitis B, Chronic/complications , Hip Fractures/etiology , Adult , Aged , Cohort Studies , Female , Hepatitis B, Chronic/drug therapy , Hip Fractures/epidemiology , Humans , Male , Middle Aged , Proportional Hazards Models , Risk
20.
Am J Public Health ; 104 Suppl 1: S152-8, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24354820

ABSTRACT

OBJECTIVES: We examined the impact of a maternal-child home visitation program on birth spacing for first-time Latina mothers, focusing on adolescents and women who identified as Mexican or Puerto Rican. METHODS: This was a retrospective cohort study. One thousand Latina women enrolled in the Pennsylvania Nurse-Family Partnership between January 1, 2003, and December 31, 2007, were matched to nonenrolled Latina women using propensity scores. The primary outcome was the time to second pregnancy that resulted in a live birth (interpregnancy interval). Proportional hazards models and bootstrap methods compared the time to event. RESULTS: Home visitation was associated with a small decrease in the risk of a short interpregnancy interval (≤ 18 months) among Latina women (hazards ratio [HR] = 0.86; 95% confidence interval [CI] = 0.75, 0.99). This effect was driven by outcomes among younger adolescent women (HR = 0.80; 95% CI = 0.65, 0.96). There was also a trend toward significance for women of Mexican heritage (HR = 0.74; 95% CI = 0.49, 1.07), although this effect might be attributed to individual agency performance. CONCLUSIONS: Home visitation using the Nurse-Family Partnership model had measurable effects on birth spacing in Latina women.


Subject(s)
Birth Intervals/statistics & numerical data , Hispanic or Latino/statistics & numerical data , Home Health Nursing , Adolescent , Educational Status , Female , Home Health Nursing/methods , Home Health Nursing/statistics & numerical data , Humans , Kaplan-Meier Estimate , Pennsylvania/epidemiology , Pregnancy/statistics & numerical data , Proportional Hazards Models , Retrospective Studies , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL